CRSP CRISPR THERAPEUTICS AG revenue, earnings and financials
For the quarter ended June 30, 2026, CRISPR THERAPEUTICS AG reported revenue of $10.2M (up 1041.4% from a year earlier), net income of −$91.2M and diluted EPS of −$0.94; over the last four quarters revenue was $13.4M and net income −$451M; for the fiscal year ended December 2025 revenue was $3.51M, down 90.6% on the year before.
CRSP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $3.51M, gross profit n/a, operating income −$665M, net income −$582M (margin -16569.8%), EPS −$6.47
- Fiscal year ended Dec 2024: revenue $37.3M, gross profit n/a, operating income −$467M, net income −$366M (margin -981.5%), EPS −$4.34
- Fiscal year ended Dec 2023: revenue $371M, gross profit n/a, operating income −$223M, net income −$154M (margin -41.4%), EPS −$1.94
- Fiscal year ended Dec 2022: revenue $1.20M, gross profit n/a, operating income −$673M, net income −$650M (margin -54271.7%), EPS −$8.36
- Fiscal year ended Dec 2021: revenue $915M, gross profit n/a, operating income $374M, net income $378M (margin 41.3%), EPS $4.70
CRSP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $10.2M (up 1041.4% year over year), net income −$91.2M, EPS −$0.94
- Quarter ended Mar 31, 2026: revenue $1.46M (up 68.6% year over year), net income −$123M, EPS −$1.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue $864K (down 97.6% year over year), net income −$131M, EPS −$1.32
- Quarter ended Sep 30, 2025: revenue $889K (up 47.7% year over year), net income −$106M, EPS −$1.17
- Quarter ended Jun 30, 2025: revenue $892K (up 72.5% year over year), net income −$209M, EPS −$2.40
- Quarter ended Mar 31, 2025: revenue $865K (up 71.6% year over year), net income −$136M, EPS −$1.58
- Quarter ended Dec 31, 2024 (from the annual report): revenue $35.7M (down 82.3% year over year), net income −$37.3M, EPS −$0.41
- Quarter ended Sep 30, 2024: revenue $602K, net income −$85.9M, EPS −$1.01
- Quarter ended Jun 30, 2024: revenue $517K (down 99.3% year over year), net income −$126M, EPS −$1.49
- Quarter ended Mar 31, 2024: revenue $504K (down 99.5% year over year), net income −$117M, EPS −$1.43
- Quarter ended Dec 31, 2023 (from the annual report): revenue $201M (up 3353333.3% year over year), net income $89.3M, EPS $1.12
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$112M, EPS −$1.41
- Quarter ended Jun 30, 2023: revenue $70.0M (up 44203.8% year over year), net income −$77.7M, EPS −$0.98
- Quarter ended Mar 31, 2023: revenue $100M (up 10538.3% year over year), net income −$53.1M, EPS −$0.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $6.00K (down 100.0% year over year), net income −$111M, EPS −$1.40
- Quarter ended Sep 30, 2022: revenue $94.0K (down 88.6% year over year), net income −$175M, EPS −$2.24
- Quarter ended Jun 30, 2022: revenue $158K (down 100.0% year over year), net income −$186M, EPS −$2.40
- Quarter ended Mar 31, 2022: revenue $940K (up 74.4% year over year), net income −$179M, EPS −$2.32
- Quarter ended Dec 31, 2021 (from the annual report): revenue $12.9M, net income −$141M, EPS −$1.56
- Quarter ended Sep 30, 2021: revenue $824K, net income −$127M, EPS −$1.67
CRSP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$345M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$143M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$260M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$496M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $539M, share buybacks n/a
CRSP balance sheet
- Jun 30, 2026: cash $291M, total assets $2.65B, total liabilities $904M, shareholders' equity $1.75B
- Mar 31, 2026: cash $423M, total assets $2.73B, total liabilities $911M, shareholders' equity $1.81B
- Dec 31, 2025: cash $348M, total assets $2.27B, total liabilities $343M, shareholders' equity $1.92B
- Sep 30, 2025: cash $286M, total assets $2.25B, total liabilities $329M, shareholders' equity $1.92B
- Jun 30, 2025: cash $194M, total assets $2.03B, total liabilities $319M, shareholders' equity $1.71B
- Mar 31, 2025: cash $235M, total assets $2.17B, total liabilities $337M, shareholders' equity $1.83B
- Dec 31, 2024: cash $298M, total assets $2.24B, total liabilities $310M, shareholders' equity $1.93B
- Sep 30, 2024: cash $226M, total assets $2.26B, total liabilities $316M, shareholders' equity $1.94B
What is CRSP's revenue?
CRISPR THERAPEUTICS AG reported $13.4M of revenue over its last four quarters, through June 30, 2026.
Is CRSP profitable?
No. CRISPR THERAPEUTICS AG lost $451M over the last four quarters.
What is CRSP's EPS?
Diluted earnings per share over the last four quarters were −$4.71; −$0.94 in the latest quarter.